LD-2 disclosure · 4th Quarter - Report
RWE ALLIANCE INC.
Client
- Name
- RWE ALLIANCE INC.
- Description
- Real-world data and analytics organizations
- Location
- District of Columbia · United States of America
Registrant
- Description
- Law firm
- Location
- Washington, District of Columbia, United States of America
Lobbying activities
2 issuesHealth Issues
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
LobbyistsWADE ACKERMAN · MORGAN SCHREURS
TargetedSENATE · HOUSE OF REPRESENTATIVES
Medical/Disease Research/Clinical Labs
Food and Drug Administration policies on real-world data and evidence in regulatory decision making; Cures 2.0 Act (H.R. 6000); PREVENT Pandemics Act (S. 3799); Food and Drug Administration Safety and Landmark Advancements (FDASLA) Act (S. 4348); Food and Drug Amendments of 2022 (H.R. 7667); Continuing Appropriations and Ukraine Supplemental Appropriations Act, 2023 (H.R.6833); Consolidated Appropriations Act, 2023 (H.R. 2617).
LobbyistsWADE ACKERMAN · MORGAN SCHREURS
TargetedSENATE · HOUSE OF REPRESENTATIVES